A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis

Status:
Completed

Trial end date:
2013-08-05

Target enrollment:

Participant gender:

The purpose of this study is to evaluate the efficacy and safety of CNTO 1959 in the treatment of patients with moderate to severe plaque psoriasis.

Phase 2

Janssen Inc.

Adalimumab